iBio Inc expected to post a loss of 7 cents a share - Earnings Preview
iBio Inc IBIO.O is expected to show a fall in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2026
The San Diego California-based company is expected to report a 80.0% decrease in revenue to $20 thousand from $100 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for iBio Inc is for a loss of 7 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for iBio Inc is $5.50, about 644.7% above its last closing price of $0.74
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | -0.07 | -0.06 | -0.07 | Missed | -9.8 |
Mar. 31 2026 | -0.07 | -0.06 | -0.06 | Met | 4.3 |
Dec. 31 2025 | -0.08 | -0.08 | -0.09 | Missed | -9.1 |
Sep. 30 2025 | -0.05 | -0.10 | -0.11 | Missed | -7.3 |
Jun. 30 2025 | -0.39 | -0.36 | -0.49 | Missed | -34.2 |
Mar. 31 2025 | -0.32 | -0.49 | Missed | -53.1 | |
Dec. 31 2024 | -0.46 | -0.46 | -0.48 | Missed | -4.3 |
Sep. 30 2024 | -0.53 | -0.48 | -0.46 | Beat | 4.2 |
This summary was machine generated November 7 at 00:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)